Why Can Cancer Cells Behave Differently Within the Same Tumor?
A tumor may look like one abnormal mass, but biologically it can contain cancer cells with surprisingly different characteristics. This phenomenon, called intratumor heterogeneity, helps explain why cancer cells can behave differently within the same tumor. Some cells may divide faster, respond differently to treatment, interact differently with immune cells, or be better equipped to survive stressful conditions than their neighbors. These differences can arise from genetic changes, changes in how genes are switched on or off, and variations in the tumor's immediate environment. Modern cancer research increasingly treats a tumor as an evolving ecosystem rather than a collection of identical cells. Understanding this diversity is important because a treatment that works against one population of cancer cells may not affect every population equally.
What Does Tumor Heterogeneity Actually Mean?
Tumor heterogeneity means that cancer is not biologically identical everywhere. Differences can exist between cancers in different people, between a person's primary tumor and metastases, and even among cells living within different regions of a single tumor.
The last of these is known as intratumor heterogeneity.
Researchers may find different genetic mutations in separate regions of the same tumor. But heterogeneity extends beyond DNA. Cells can also differ in gene activity, metabolism, appearance, ability to divide, interactions with surrounding tissue and sensitivity to treatment.
The National Cancer Institute definition of tumor heterogeneity describes this diversity as differences between tumors of the same type, differences between cancer cells within a single tumor, or differences between a primary tumor and a secondary tumor.
A tumor is more like an ecosystem than a clone army
Many cancer cells within a tumor share a common ancestry, but they do not necessarily remain identical.
As cancer develops, cells continue dividing. New biological changes can arise, while conditions surrounding different groups of cells can also influence how they function.
A useful way to picture this is as a branching tree. Cells near the trunk share early changes, while different branches acquire additional characteristics over time. The result can be several related but biologically distinct populations living inside the same tumor.
Cancer cells within one tumor can differ at several biological levels.
Type of difference | What can vary | Why it may matter |
Genetic | DNA mutations and chromosome changes | Different cell populations may gain different survival advantages |
Epigenetic | How genes are switched on or off without changing the DNA sequence | Cells with similar DNA can behave differently |
Gene expression | Which genes are actively producing RNA and proteins | Can alter growth, metabolism and treatment response |
Metabolic | How cells obtain and use energy | May help cells adapt to oxygen or nutrient shortages |
Microenvironmental | Oxygen, nutrients, immune activity and surrounding cells | Different tumor regions can place different pressures on cancer cells |
Treatment sensitivity | Vulnerability to drugs or other therapies | Some populations may survive while others are eliminated |
How Do Different Cancer Cell Populations Develop Within One Tumor?
Different cancer cell populations can emerge as tumors evolve. Cancer cells accumulate biological changes over successive generations, and cells possessing characteristics that improve survival or reproduction under particular conditions may become more prominent.
This process is often described as clonal evolution.
Cancer evolution can create branches
Imagine that one cancer cell develops a change that gives it a growth advantage. As that cell divides, its descendants inherit the change and form a population, or clone.
Later, a cell within that population might acquire another change. Somewhere else in the tumor, another cell lineage may acquire a different one.
Instead of progressing along one uniform path, tumor evolution can therefore branch.
A landmark multiregion sequencing study of kidney cancer demonstrated this principle by analyzing genetically separated areas from individual tumors and associated metastases. Researchers found substantial intratumor heterogeneity and evidence of branched evolutionary patterns. The multiregion sequencing study of intratumor heterogeneity helped illustrate why a sample from one tumor region may not capture every genetic alteration present elsewhere.
Importantly, not every mutation gives cancer cells an advantage. Many genetic changes may have little functional effect, while some—often called driver alterations—can contribute to cancer development or progression.
Two cancer cells living in the same tumor can share the mutations that helped establish the cancer yet differ in later changes acquired as the tumor evolved. Those differences can influence how individual cell populations grow, survive and respond to their surroundings or treatment.
Can Cancer Cells Behave Differently Even When Their DNA Is Similar?
Yes. Genetic mutations are only one source of tumor diversity. Cancer cells with very similar DNA can sometimes behave differently because cells regulate genes differently and can shift between biological states.
One important mechanism is epigenetic regulation. Epigenetic changes affect gene activity without necessarily altering the underlying DNA sequence.
Cells can switch biological states
A cell does not use every gene in its genome simultaneously. Instead, different combinations of genes become more or less active depending on the cell's state and surrounding signals.
That flexibility can produce meaningful differences between neighboring cancer cells.
For example, one group of cells may strongly express genes involved in cell division, while another population may temporarily divide more slowly. Other cells may activate stress-response, metabolic, invasion or survival programs.
This phenomenon is sometimes called cellular plasticity—the ability of cells to change their state or characteristics in response to internal or environmental signals.
Modern single-cell technologies have made these differences much easier to investigate. Rather than averaging signals across thousands or millions of tumor cells, researchers can examine molecular characteristics cell by cell.
The National Cancer Institute Human Tumor Atlas Network is one initiative using advanced spatial and single-cell approaches to characterize how cancers develop, progress and respond to treatment.
How Does the Tumor Microenvironment Change Cancer Cell Behavior?
Cancer cells do not live alone. They exist within a complex tumor microenvironment containing blood vessels, immune cells, connective-tissue cells, extracellular material and signaling molecules.
Conditions can vary considerably from one part of a tumor to another.
Some tumor regions receive less oxygen
As a tumor grows, its blood-vessel network may not supply every region equally. Some areas can therefore receive less oxygen, creating hypoxia.
Cells exposed to hypoxia can activate biological programs that help them adapt to low-oxygen conditions. These responses can alter metabolism, gene expression and interactions with surrounding tissue.
Other tumor regions may have better blood flow and different nutrient availability. Cancer cells only a relatively short distance apart can therefore experience different environments.
Immune pressure is not uniform either
Immune cells are another major component of many tumor microenvironments.
Some tumor areas may contain substantial numbers of immune cells, while other regions may have fewer. Cancer cells can also develop mechanisms that reduce immune recognition or suppress aspects of an immune response.
These interactions create additional selection pressures. Cells capable of surviving particular local conditions may persist while more vulnerable populations disappear.
Different environments within the same tumor can push cancer cells toward different behaviors.
Local condition | Possible cellular response | Potential significance |
Low oxygen | Metabolic and gene-expression changes | May help cells adapt to hypoxic regions |
Limited nutrients | Alternative metabolic strategies | |
Immune-cell activity | Selection for cells better able to avoid or suppress immune attack | May contribute to immune escape |
Different growth signals | Changes in proliferation and survival pathways | Some populations may grow faster than others |
Drug exposure | Sensitive cells may die while resistant populations survive | Tumor composition can change during treatment |
Interaction with surrounding cells | Altered signaling and cellular behavior | May influence growth, invasion and treatment response |
Why Does Tumor Heterogeneity Matter for Cancer Treatment?
Tumor heterogeneity matters because treatment does not necessarily affect every cancer cell equally. If different cell populations depend on different biological pathways or have different drug sensitivities, therapy can eliminate some populations while leaving others alive.
This creates an important problem known as treatment resistance.
Treatment itself can create selection pressure
Consider a simplified tumor containing mostly treatment-sensitive cells but also a much smaller population with characteristics that allow it to survive a particular drug.
Treatment may kill a large proportion of the sensitive cells. The resistant population, however, can remain.
With less competition for space and resources, surviving cells may eventually expand. A cancer that initially shrank can therefore later begin growing again.
Resistance does not always mean resistant cells were present from the beginning. New genetic changes can arise during tumor evolution, and cancer cells may also adapt through non-genetic mechanisms.
One biopsy may not reveal every tumor population
A biopsy samples tissue from a particular location. If biologically distinct populations occupy different tumor regions, that sample may not represent every cancer cell in the tumor.
This does not make biopsies unreliable or unhelpful—they remain central to cancer diagnosis and molecular testing. Rather, intratumor heterogeneity is one reason clinicians and researchers must interpret a tissue sample within its clinical context.
In selected cancers, additional biopsies, blood-based molecular tests or repeated testing as disease changes may sometimes provide further information. Whether these approaches are useful depends on the specific cancer and clinical situation.
Can Cancer Cells Change During Treatment or When Cancer Spreads?
Yes. Tumors can continue evolving during cancer progression and treatment, so their biological composition may change over time. Metastatic tumors can also differ from the original tumor and from one another.
This is sometimes described as temporal heterogeneity—variation that emerges over time.
When cancer spreads, only certain cells successfully complete the complicated process required to leave the original tumor, survive elsewhere in the body and establish another tumor. The resulting metastasis therefore may not contain exactly the same mixture of cancer-cell populations as the primary tumor.
Treatment adds another evolutionary pressure. Populations vulnerable to therapy may shrink substantially, while populations capable of surviving can become proportionally more important.
The National Cancer Institute overview of drug resistance in cancer explains that resistance can exist before treatment or develop while cancer is being treated.
These principles help explain why oncologists may sometimes reconsider molecular testing or treatment strategy when cancer progresses. The appropriate approach, however, depends strongly on cancer type, stage, previous treatment and the individual patient's clinical circumstances.
What Does Tumor Heterogeneity Mean for Patients?
Tumor heterogeneity helps explain several realities of cancer care, but it should not be interpreted as meaning treatment cannot work. Many cancers respond substantially—and sometimes durably—to therapy despite considerable biological complexity.
For patients, the practical significance depends on the particular cancer.
Pathology, molecular biomarkers, imaging, cancer stage and treatment response can all provide different pieces of information. Some cancers now have validated biomarkers that help doctors select targeted therapies or immunotherapies, while other cancers are primarily treated according to different clinical characteristics.
It is also important not to interpret a single molecular result without context. Finding a mutation does not automatically mean a particular medicine will work, and detecting tumor heterogeneity does not by itself determine prognosis.
Questions about tumor sequencing, repeat biopsies, liquid biopsies or treatment resistance should therefore be discussed with the treating oncology team, which can interpret these findings for the specific cancer and available evidence.
Conclusion
Cancer cells can behave differently within the same tumor because tumors continually accumulate biological diversity. Genetic evolution, epigenetic changes, shifting cell states, unequal oxygen and nutrient availability, immune interactions and treatment pressure can all produce populations with different characteristics. This intratumor heterogeneity helps researchers understand why one tumor region may differ from another and why treatment resistance can sometimes emerge.
These discoveries are improving how scientists study cancer, but their clinical importance varies considerably by cancer type and patient. Molecular findings should therefore be interpreted by an oncology team alongside pathology, stage, treatment history and validated clinical evidence rather than used alone to make treatment decisions.
Frequently Asked Questions
1. Are all cancer cells inside one tumor genetically identical?
No. Cancer cells within one tumor usually share important ancestral changes but can acquire additional genetic differences as the cancer evolves. Different groups of related cells, called clones or subclones, can therefore coexist within the same tumor and may have different biological characteristics.
2. What is intratumor heterogeneity in simple terms?
Intratumor heterogeneity means that different cells or regions within one tumor are not biologically identical. They can differ in mutations, gene activity, metabolism and interactions with surrounding tissue. These differences can influence how individual cancer-cell populations grow or respond to treatment.
3. Can two cancer cells with similar DNA behave differently?
Yes. Cells with similar DNA can activate different genes or occupy different biological states. Epigenetic regulation, local environmental conditions and cellular signals can alter cell behavior without requiring a new DNA mutation, adding another layer of diversity within tumors.
4. Why can cancer treatment kill some tumor cells but not others?
Different cancer-cell populations may have different treatment sensitivities. A therapy can eliminate susceptible cells while cells with resistant genetic or non-genetic characteristics survive. Those surviving populations may later expand, which is one mechanism that can contribute to treatment resistance.
5. Can one biopsy show everything about a tumor?
A biopsy provides important information about the tissue sampled, but biologically different regions can sometimes exist elsewhere in a tumor. This sampling limitation does not make biopsies ineffective. Whether additional or repeat testing is useful depends on the cancer and clinical circumstances.
6. Does tumor heterogeneity mean cancer cannot be successfully treated?
No. Tumor heterogeneity can make treatment more complicated, particularly when resistant cell populations emerge, but it does not mean therapy cannot work. Treatment outcomes depend on cancer type, stage, molecular features, available therapies and many other clinical factors.
Comments